Taking Bold Bets: NIH and the Future of Biomedical Science

Bhattacharya describes autism prevalence as high and rising and says NIH lacks actionable causal answers; the new $50M initiative is designed to fund teams capable of integrating datasets and producing clearer, testable hypotheses over the next few years.

He claims folinic acid can help children with specific folate-processing issues, citing effects like speech restoration in a minority and broader improvement in others, while emphasizing that benefits depend on subtype/biology and should be made more accessible via coverage and guidance.

He references newer studies suggesting correlation with later autism diagnoses and supports updated FDA guidance that encourages limited, need-based use (e.g., high fevers) without “panic,” reflecting uncertainty rather than definitive causality.

He argues scientists gain little career reward for replication and negative results often go unpublished; raising standards and funding independent verification would reduce false confidence and improve downstream translation to health benefits.

Bhattacharya contrasts venture portfolios (many failures, a few transformative wins) with NIH’s increasing conservatism, noting funded ideas have aged over decades; he proposes tolerating “productive failure” and enabling publication of what didn’t work and why.